Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future

Abstract

Neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease represent a crucial and exponentially increasing challenge to health care systems throughout the world. There is an urgent need for effective treatments that will both delay their onset and slow their inexorable progression. Many obstacles stand in the way of realizing these goals. It is expected that future advances will have a major impact on how and when the diagnosis will be made. It is hoped that these will eventually make it possible to initiate effective disease-modifying therapies long before the neurodegenerative process becomes established and symptomatic.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Theoretical effects of disease modifying treatments in Parkinson's disease.

References

  1. The Lewin Group. Saving lives, saving money: dividends for Americans investing in Alzheimer's Research. (Falls Church, Virginia, USA, 2004).

  2. Alzheimer's Association. <http://www.alz.org/documents_custom/trajectory.pdf> (2010).

  3. Alzheimer's Disease International. <http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf> (2009).

  4. Dorsey, E.R. et al. Neurology 68, 384–386 (2007).

    Article  CAS  Google Scholar 

  5. DeKosky, S.T. & Marek, K. Science 302, 830–834 (2003).

    Article  CAS  Google Scholar 

  6. Brookmeyer, R., Gray, S. & Kawas, C. Am. J. Public Health 88, 1337–1342 (1998).

    Article  CAS  Google Scholar 

  7. Olanow, C.W., Kieburtz, K. & Schapira, A.H. Ann. Neurol. 64 Suppl 2, S101–S110 (2008).

    CAS  Google Scholar 

  8. Francis, P.T., Norberg, A. & Arnold, S.E. Trends Pharmacol. Sci. 26, 104–111 (2005).

    Article  CAS  Google Scholar 

  9. Brooks, D.J. Ann. Neurol. 44, S10–S18 (1998).

    Article  CAS  Google Scholar 

  10. Broussolle, E. et al. Neurology 55, 877–879 (2000).

    Article  CAS  Google Scholar 

  11. Levy, G. Arch. Neurol. 64, 1242–1246 (2007).

    Article  Google Scholar 

  12. Levy, G. et al. Arch. Neurol. 62, 467–472 (2005).

    Article  Google Scholar 

  13. Aarsland, D. et al. J. Neurol. 254, 38–45 (2007).

    Article  CAS  Google Scholar 

  14. Jenner, P. Ann. Neurol. 64, S16–S29 (2008).

    Article  CAS  Google Scholar 

  15. Dawson, T.M., Ko, H.S. & Dawson, V.L. Neuron 66, 646–661 (2010).

    Article  CAS  Google Scholar 

  16. Ashe, K.H. & Zahs, K.R. Neuron 66, 631–645 (2010).

    Article  CAS  Google Scholar 

  17. Epis, R. et al. Eur. J. Pharmacol. 626, 57–63 (2010).

    Article  CAS  Google Scholar 

  18. Kokjohn, T.A. & Roher, A.E. Alzheimers Dement. 5, 340–347 (2009).

    Article  CAS  Google Scholar 

  19. Philipson, O. et al. FEBS J. 277, 1389–1409 (2010).

    Article  CAS  Google Scholar 

  20. Lang, A.E. Lancet Neurol. 5, 990–991 (2006).

    Article  Google Scholar 

  21. Jucker, M. Nat. Med. published online, 10.1038/nm.2224 (21 September 2010)

    Google Scholar 

  22. Hirsch, E.C. & Hunot, S. Lancet Neurol. 8, 382–397 (2009).

    Article  CAS  Google Scholar 

  23. Aisen, P.S. et al. Alzheimers Dement. 6, 239–246 (2010).

    Article  Google Scholar 

  24. Trojanowski, J.Q. et al. Alzheimers Dement. 6, 230–238 (2010).

    Article  CAS  Google Scholar 

  25. Weiner, M.W. et al. Alzheimers Dement. 6, 202–211 (2010).

    Article  Google Scholar 

  26. Ravina, B. et al. Mov. Disord. 24, 2081–2090 (2009).

    Article  Google Scholar 

  27. Scherzer, C.R. Neurobiol. Dis. 35, 148–156 (2009).

    Article  CAS  Google Scholar 

  28. Hampel, H. et al. Nat. Rev. Drug Discov. 9, 560–574 (2010).

    Article  CAS  Google Scholar 

  29. Blennow, K. Nat. Med. published online, 10.1038/nm.2221 (21 September 2010).

    Google Scholar 

  30. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Nat. Rev. Neurol. 6, 131–144 (2010).

    Article  CAS  Google Scholar 

  31. Fahn, S. et al. N. Engl. J. Med. 351, 2498–2508 (2004).

    Article  CAS  Google Scholar 

  32. Dubois, B. et al. Lancet Neurol. 6, 734–746 (2007).

    Article  Google Scholar 

  33. Siderowf, A. & Stern, M.B. Ann. Neurol. 64, S139–S147 (2008).

    Article  Google Scholar 

  34. Ponsen, M.M., Stoffers, D., Twisk, J.W.R., Wolters, E.C. & Berendse, H.W. Mov. Disord. 24, 1060–1065 (2009).

    Article  Google Scholar 

  35. Haehner, A. et al. Mov. Disord. 22, 839–842 (2007).

    Article  Google Scholar 

  36. Kieburtz, K. Neurology 66, S50–S57 (2006).

    Article  Google Scholar 

  37. Parkinson Study Group. N. Engl. J. Med. 321, 1364–1371 (1989).

  38. Parkinson Study Group PRECEPT Investigators et al. Neurology 69, 1480–1490 (2007)

  39. Olanow, C.W. et al. Lancet Neurol. 5, 1013–1020 (2006).

    Article  CAS  Google Scholar 

  40. Leber, P. Alzheimer Dis. Assoc. Disord. 11 Suppl 5, S10–S21 (1997).

    PubMed  Google Scholar 

  41. Olanow, C.W. et al. Mov. Disord. 23, 2194–2201 (2008).

    Article  Google Scholar 

  42. Clarke, C.E. Mov. Disord. 23, 784–789 (2008).

    Article  Google Scholar 

  43. D'Agostino, R.B. Sr. N. Engl. J. Med. 361, 1304–1306 (2009).

    Article  CAS  Google Scholar 

  44. Ploeger, B.A. & Holford, N.H. Pharm. Stat. 8, 225–238 (2009).

    Article  Google Scholar 

  45. Parkinson Study Group et al. J. Am. Med. Assoc. 287, 1653–1661 (2002).

  46. Whone, A.L. et al. Ann. Neurol. 54, 93–101 (2003).

    Article  CAS  Google Scholar 

  47. Freed, C.R. et al. N. Engl. J. Med. 344, 710–719 (2001).

    Article  CAS  Google Scholar 

  48. Olanow, C.W. et al. Ann. Neurol. 54, 403–414 (2003).

    Article  Google Scholar 

  49. Tang, C.C., Poston, K.L., Dhawan, V. & Eidelberg, D. J. Neurosci. 30, 1049–1056 (2010).

    Article  CAS  Google Scholar 

  50. Eckert, T., Tong, C. & Eidelberg, D. Lancet Neurol. 6, 926–932 (2007).

    Article  Google Scholar 

  51. Lim, S.Y., Fox, S.H. & Lang, A.E. Arch. Neurol. 66, 167–172 (2009).

    PubMed  Google Scholar 

  52. Huang, P. et al. Mov. Disord 24, 1732–1739 (2009).

    Article  Google Scholar 

  53. NINDS NET-PD Investigators et al. Neurology 68, 20–28 (2007).

  54. Salloway, S. et al. Neurology 73, 2061–2070 (2009).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

I thank B. Greenberg for his helpful comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anthony E Lang.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lang, A. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 16, 1223–1226 (2010). https://doi.org/10.1038/nm.2220

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2220

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research